$41.16
arrow_drop_down1.64%There's no data available for key stats
There's no data available for ratios/profitability stats
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
Celldex Therapeutics to Present at Jefferies Healthcare Conference
Analyst Expectations For Celldex Therapeutics's Future
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis